Here are the 10-K annual reports from PAVmed Inc. (PAVM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PAVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVM filings page.
PAVmed Inc. files its annual report describing a diversified life sciences business built around Lucid Diagnostics’ EsoGuard/EsoCheck esophageal precancer tests, the Veris Cancer Care digital platform, and a developing medical device pipeline including PortIO and new endoscopic imaging technology licensed from Duke University.
The company highlights reimbursement and adoption progress for EsoGuard, including a U.S. Department of Veterans Affairs contract and commercial insurer coverage, as well as a strategic Veris partnership with Ohio State’s cancer center. PAVmed also completed a $30 million Series D preferred financing, a 1‑for‑30 reverse stock split to regain Nasdaq compliance, multiple equity raises at Lucid and Veris, and a recapitalization that produced about $7.6 million in net proceeds. Management nonetheless reports continued operating losses and explicitly notes substantial doubt about the company’s ability to continue as a going concern, underscoring heavy reliance on ongoing access to capital.